Alnylam Pharmaceuticals (ALNY) reported third-quarter 2026 revenue of $1.46 billion, up 17% from a year earlier. GAAP net income was $2.17 billion, or $16.19 per basic share and $15.72 per diluted share.
Total net product revenue rose 52% to $1.29 billion, led by $1.15 billion in TTR product revenue. The company reiterated its full-year 2026 financial guidance.
- AMVUTTRA revenue was $1.13 billion, up 65% year over year.
- ONPATTRO revenue was $19.6 million, down 50% year over year.
- GIVLAARI and OXLUMO generated revenue of $89.5 million and $52.5 million, respectively.
- Alnylam expanded the TRITON-CM Phase 3 target enrollment for nucresiran to about 2,250 patients and expects a potential ATTR-CM launch by 2030, subject to positive data and regulatory approval.
- Cash, cash equivalents and marketable securities totaled $3.6 billion as of September 30, 2026.
$ALNY Insider Trading Activity
$ALNY insiders have traded $ALNY stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- DAVID E I PYOTT has made 0 purchases and 5 sales selling 3,830 shares for an estimated $1,145,852.
- BRYAN SUPRAN (EVP, CLO and Secretary) sold 1,758 shares for an estimated $398,855
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALNY Hedge Fund Activity
We have seen 401 institutional investors add shares of $ALNY stock to their portfolio, and 357 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 4,490,826 shares (+390.0%) to their portfolio in Q2 2026, for an estimated $1,351,873,350
- JPMORGAN CHASE & CO added 2,675,517 shares (+inf%) to their portfolio in Q2 2026, for an estimated $805,410,882
- INVESCO LTD. added 2,462,592 shares (+190.6%) to their portfolio in Q2 2026, for an estimated $741,314,069
- MARSHALL WACE, LLP removed 839,519 shares (-76.4%) from their portfolio in Q2 2026, for an estimated $252,720,404
- DEEP TRACK CAPITAL, LP added 825,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $248,349,749
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 755,377 shares (+inf%) to their portfolio in Q2 2026, for an estimated $227,391,138
- D. E. SHAW & CO., INC. added 659,616 shares (+148.4%) to their portfolio in Q2 2026, for an estimated $198,564,204
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALNY Congressional Stock Trading
Members of Congress have traded $ALNY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by members of Congress over the last 6 months:
- SENATOR CORY A. BOOKER sold up to $15,000 on 08/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
